DexCom, Inc. vs TeraWulf Inc — how do they compare? DexCom, Inc. trades at $90.39 (market cap $33.79B), while TeraWulf Inc trades at $17.15 (market cap $8.35B). The key difference: DexCom, Inc. is far larger — about 4× TeraWulf Inc's market cap, and DexCom, Inc. is trading nearer its 52-week high, TeraWulf Inc nearer its low. Which is the better fit depends on your goals.
| DXCM | WULF | |
|---|---|---|
Market Cap | $33.79B | $8.35B |
Sector | Health | Technology |
52-Week High | $89.53 | $28.98 |
52-Week Low | $54.84 | $5.24 |
Enterprise Value | $33.24B | $10.97B |
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $90.23, up 2.94% today and near its 52-week high, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating EPS estimates with $0.70 versus $0.61 expected, and raised full-year guidance. Revenue growth remains robust at 13% year-over-year, supported by G7 system adoption and international expansion. Profit margins improved, with net income margin reaching 20.12% in 2025. Analyst sentiment is overwhelmingly positive, with 80% buy ratings.
The outlook for DXCM is favorable due to sustained demand for continuous glucose monitors and strategic initiatives like 'Road to 100'. Key risks include competitive pressures, regulatory scrutiny, and valuation multiples above industry averages. The stock's current price is slightly above the consensus target of $88.65, suggesting near-term consolidation may occur before further upside.
WULF trades at $17.04, up 5.19% on the day amid a broader neocloud infrastructure rally. The stock shows bearish technical signals with 17 sell signals versus 2 buys, while fundamentals reveal significant challenges with a -1,179.94% net income margin and consistent earnings misses. Recent Q2 2026 results showed a $0.37 per share loss versus $0.20 expected, though revenue beat estimates. The company is expanding its high-performance computing capacity with 102 MW operational and 336 MW under construction, supported by a major Anthropic leasing agreement.
Despite unanimous analyst buy ratings and a $38 consensus price target representing 123% upside, WULF faces substantial execution risks and profitability concerns. The transition to AI infrastructure offers long-term potential, but near-term losses and high capital requirements create volatility. Investors should weigh the significant growth opportunity against persistent negative cash flow and competitive pressures in the evolving data center market.
Trailing returns across standard periods
Latest headlines on both assets
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →TeraWulf develops, owns, and operates fully integrated digital infrastructure powered by predominantly zero-carbon energy. It utilizes a hybrid business model that combines industrial-scale Bitcoin mining with high-performance computing (HPC) and AI hosting, leveraging sustainable power sources like nuclear and hydroelectric to deliver low-cost, energy-efficient data center solutions.
Read more on WULF →